SCHEMBL1166369

SCHEMBL1166369

CC(=O)c1ccc(Cn2cc(NC(=O)OCc3c(F)cccc3Cl)cn2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.49
▸ HCRTR1 O43613 1/20 0.47
▸ HCRTR2 O43614 1/20 0.47
▸ SCN9A Q15858 5/20 0.45
▸ SCN5A Q14524 3/20 0.45
▸ ALDH1A1 P00352 7/20 0.44
▸ MAPT P10636 4/20 0.44
▸ HTT P42858 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ SCD O00767 2/20 0.44
▸ SCD5 Q86SK9 2/20 0.44
▸ POLB P06746 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1166836 0.94 HCRTR1 (0.51) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1166176 0.90 MEN1 (0.44) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1166349 0.88 HCRTR1 (0.47) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1166373 0.87 HCRTR1 (0.45) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1166008 0.87 HCRTR1 (0.45) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1165908 0.86 KDM4E (0.48) KDM4ESCN9ASCN5AALDH1A1MAPT
SCHEMBL1166388 0.86 HCRTR1 (0.49) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1166419 0.86 HCRTR1 (0.48) KDM4EHCRTR1HCRTR2SCN9ASCN5A
SCHEMBL1166315 0.86 HCRTR1 (0.48) KDM4EHCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL1167144 0.86 HCRTR1 (0.48) KDM4EHCRTR1HCRTR2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 — — EP claimed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 — — US claimed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 — — US claimed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 — — EP claimed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 — — WO claimed
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 — — EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 — — US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 — — US disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 — — EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 KDM4E 1994/4885HCRTR1 2862/4885HCRTR2 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback